James E Flynn Insider Trading $ADVM Adverum Biotechnologies, Inc.
Get free email notifications about insider trading for James E Flynn.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of James E Flynn. James E Flynn is 10% Owner in CAS MEDICAL SYSTEMS INC ($CAMY.OB) and 10% Owner in AxoGen, Inc. ($LECT) and 10% Owner in PAR PHARMACEUTICAL COMPANIES, INC. ($PRX) and 10% Owner in Fibrocell Science, Inc. ($FCSC) and 10% Owner in STREAMLINE HEALTH SOLUTIONS INC. ($LANV) and 10% Owner in ANTARES PHARMA, INC. ($ATRS) and 10% Owner in VIA Pharmaceuticals, Inc. ($CAQ) and 10% Owner in DUSA PHARMACEUTICALS INC ($DUSA) and 10% Owner in HI TECH PHARMACAL CO INC ($HITK) and 10% Owner in AVADEL PHARMACEUTICALS PLC ($AVDL) and 10% Owner in INSPIRE PHARMACEUTICALS INC ($ISPH) and 10% Owner in RIGEL PHARMACEUTICALS INC ($RIGL) and 10% Owner in ARENA PHARMACEUTICALS INC ($ARNA) and 10% Owner in ISTA PHARMACEUTICALS INC ($ISTA) and 10% Owner in MEDICINES CO /DE ($MDCO) and 10% Owner in THIRD WAVE TECHNOLOGIES INC /WI ($TWTI) and 10% Owner in DYNAVAX TECHNOLOGIES CORP ($DVAX) and 10% Owner in Cyclacel Pharmaceuticals, Inc. ($CYCC) and Director in Talon Therapeutics, Inc. ($EMLR) and 10% Owner in LUMOS PHARMA, INC. ($NLNK) and 10% Owner in NITROMED INC ($NTMD) and 10% Owner in XENOPORT INC ($XNPT) and 10% Owner in EMAGEON INC ($EMAG) and 10% Owner in CATALYST BIOSCIENCES, INC. ($CBIO) and 10% Owner in ALIMERA SCIENCES INC ($ALIM) and 10% Owner in NeuroMetrix, Inc. ($NURO) and 10% Owner in NxStage Medical, Inc. ($NXTM) and 10% Owner in aTYR PHARMA INC ($LIFE) and 10% Owner in Vanda Pharmaceuticals Inc. ($VNDA) and 10% Owner in XERIS PHARMACEUTICALS INC ($XERS) and Director in PROTEON THERAPEUTICS INC ($PRTO) and 10% Owner in eHealth, Inc. ($EHTH) and 10% Owner in ZAFGEN, INC. ($ZFGN) and 10% Owner in NeurogesX Inc ($NGSX) and 10% Owner in Invuity, Inc. ($IVTY) and 10% Owner in Dicerna Pharmaceuticals Inc ($DRNA) and 10% Owner in CONSTELLATION PHARMACEUTICALS INC ($CNST) and 10% Owner in TriVascular Technologies, Inc. ($TRIV) and 10% Owner in Auspex Pharmaceuticals, Inc. ($ASPX) and 10% Owner in Neos Therapeutics, Inc. ($NEOS) and 10% Owner in Schrodinger, Inc. ($SDGR) and 10% Owner in CytomX Therapeutics, Inc. ($CTMX) and Director in Acutus Medical, Inc. ($AFIB) and 10% Owner in Annexon, Inc. ($ANNX) and 10% Owner in Aclaris Therapeutics, Inc. ($ACRS) and 10% Owner in Syros Pharmaceuticals, Inc. ($SYRS) and 10% Owner in Mallinckrodt plc ($MNK) and 10% Owner in Loxo Oncology, Inc. ($LOXO) and 10% Owner in Adverum Biotechnologies, Inc. ($AAVL) and 10% Owner in REGENXBIO Inc. ($RGNX) and 10% Owner in Recro Pharma, Inc. ($REPH) and 10% Owner in Nivalis Therapeutics, Inc. ($NVLS) and Director in Nivalis Therapeutics, Inc. ($NVLS) and 10% Owner in Audentes Therapeutics, Inc. ($BOLD) and 10% Owner in SteadyMed Ltd. ($STDY) and 10% Owner in ShockWave Medical, Inc. ($SWAV) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and 10% Owner in Editas Medicine, Inc. ($EDIT) and Director in AveXis, Inc. ($AVXS) and 10% Owner in ARVINAS INC. ($ARVN) and 10% Owner in Homology Medicines, Inc. ($FIXX) and Director in Homology Medicines, Inc. ($FIXX) and Director in Oncorus, Inc. ($ONCR) and 10% Owner in Revolution Medicines, Inc. ($RVMD) and 10% Owner in Black Diamond Therapeutics, Inc. ($BDTX) and 10% Owner in Frequency Therapeutics, Inc. ($FREQ) and Director in DFB Healthcare Acquisitions Corp. ($DFBH) and 10% Owner in Generation Bio Co. ($GBIO) and 10% Owner in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and 10% Owner in Mirum Pharmaceuticals, Inc. ($MIRM) and 10% Owner in Cabaletta Bio, Inc. ($CABA) and 10% Owner in Werewolf Therapeutics, Inc. ($HOWL) and 10% Owner in Nkarta, Inc. ($NKTX) and 10% Owner in Edgewise Therapeutics, Inc. ($EWTX) and Director in DFP HEALTHCARE ACQUISITIONS CORP. ($DFPH) and Director in Deerfield Healthcare Technology Acquisitions Corp. ($DFHT) and 10% Owner in Terns Pharmaceuticals, Inc. ($TERN).
James E Flynn in Adverum Biotechnologies, Inc.
Trading Symbol: ADVMIndustry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of James E Flynn: 10% Owner
Holdings: 627,267 shares
Latest Transaction: Aug 05 2014
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of James E Flynn in Adverum Biotechnologies, Inc.
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACRS, AFIB, DFBH, ADVM, ALIM, ALPN, ANNX, ATRS, ARNA, ARVN, LIFE, BOLD, ASPX, AVDL, AVXS, LECT, BDTX, CABA, CAMY.OB, CBIO, CNST, CYCC, CTMX, DFHTW, DFPHU, DRNA, DUSA, DVAX, EWTX, EDIT, EHTH, EMAG, FCSC, FREQ, GBIO, HITK, FIXX, ISPH, IVTY, ISTA, KNSA, LRMR, LOXO, NLNK, MNK, MDCO, MIRM, NEOS, NGSX, NURO, NTMD, NKTX, NXTM, ONCR, PRX, TARA, REPH, RGNX, RVMD, RYTM, RIGL, SDGR, SWAV, STDY, LANV, SYRS, EMLR, TERN, TWTI, TRIV, VNDA, CAQ, HOWL, XNPT, XERS
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 531,208 | 0 | 0 | |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 147,410 | 0 | 0 | |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 184,594 | 0 | 0 | |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 24.57 | 31,650 | 777,641 | 627,267 | 595.6 K to 627.3 K (+5.31 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 26.35 | 49,981 | 1,316,999 | 595,617 | 545.6 K to 595.6 K (+9.16 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 26.14 | 27,600 | 721,464 | 545,636 | 518 K to 545.6 K (+5.33 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 27.54 | 12,400 | 341,496 | 518,036 | 505.6 K to 518 K (+2.45 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 26.42 | 219,864 | 5,808,807 | 505,636 | 285.8 K to 505.6 K (+76.94 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 25.79 | 18,700 | 482,273 | 285,772 | 267.1 K to 285.8 K (+7.00 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 25.52 | 9,800 | 250,096 | 267,072 | 257.3 K to 267.1 K (+3.81 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 25.41 | 201,972 | 5,132,109 | 257,272 | 55.3 K to 257.3 K (+365.23 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 55,300 | 940,100 | 55,300 | 0 to 55.3 K |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 24.57 | 25,600 | 628,992 | 507,200 | 481.6 K to 507.2 K (+5.32 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 26.35 | 40,400 | 1,064,540 | 481,600 | 441.2 K to 481.6 K (+9.16 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 26.14 | 22,400 | 585,536 | 441,200 | 418.8 K to 441.2 K (+5.35 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 27.54 | 10,100 | 278,154 | 418,800 | 408.7 K to 418.8 K (+2.47 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 26.42 | 177,700 | 4,694,834 | 408,700 | 231 K to 408.7 K (+76.93 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 25.79 | 15,100 | 389,429 | 231,000 | 215.9 K to 231 K (+6.99 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 25.52 | 7,900 | 201,608 | 215,900 | 208 K to 215.9 K (+3.80 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 25.41 | 163,300 | 4,149,453 | 208,000 | 44.7 K to 208 K (+365.32 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 44,700 | 759,900 | 44,700 | 0 to 44.7 K |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 123,077 | 2,092,309 | 654,285 | 531.2 K to 654.3 K (+23.17 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 34,223 | 581,791 | 181,633 | 147.4 K to 181.6 K (+23.22 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 42,700 | 725,900 | 227,294 | 184.6 K to 227.3 K (+23.13 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 531,208 | 0 | 531,208 | 0 to 531.2 K |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 147,410 | 0 | 147,410 | 0 to 147.4 K |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 184,594 | 0 | 184,594 | 0 to 184.6 K |
Page: 1